Ganirelix Other names: Ganirelix acetate Ganirelix diacetate

Chemical formula: C₈₀H₁₁₃ClN₁₈O₁₃ Molecular mass: 1,570.35 g/mol PubChem compound: 16130957

Therapeutic indications

Ganirelix is indicated for:

Prevention of premature luteinising hormone (LH) surges in controlled ovarian hyperstimulation (COH)

Population group: women, only adults (18 - 65 years old)

Ganirelix is indicated for the prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).

In clinical studies ganirelix was used with recombinant human follicle stimulating hormone (FSH) or corifollitropin alfa, the sustained follicle stimulant.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.25 mg once daily starting on day 5 or day 6 of FSH administration

Contraindications

Ganirelix is contraindicated in the following cases:

Pregnancy

Lactation

Moderate or severe impairment of hepatic function

at least one of

Hepatic failure stage III
Hepatic failure stage IV

Moderate or severe impairment of renal function

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.